Benefits
LDL cholesterol reduction
Replacing meat with mycoprotein in the diet reduces LDL cholesterol over weeks of consistent intake. Effect is mediated by the soluble fiber content and saturated fat reduction compared to red meat — cardiovascular benefit beyond pure protein replacement.
Satiety and weight management
Mycoprotein produces higher satiety than equivalent meat or vegetarian protein servings — likely due to high fiber content and unique texture. Studies show reduced energy intake at subsequent meals after mycoprotein meals.
Improved glycemic response
Compared to similar protein servings from animal sources, mycoprotein meals produce lower post-meal glucose and insulin responses. Particularly relevant for prediabetes and metabolic syndrome management.
Complete plant-based protein
Provides all essential amino acids in roughly the proportions needed for human protein synthesis. Sufficient for muscle building when consumed in adequate servings — though leucine content is somewhat lower than whey, requiring slightly higher total intake for equivalent muscle protein synthesis.
Sustainable protein production
Mycoprotein production has substantially lower environmental impact than animal protein — less land use, less water, lower greenhouse gas emissions. Sustainability advantage matters for those prioritizing dietary environmental footprint.
Mechanism of action
Bile acid sequestration and cholesterol reduction
Mycoprotein's fungal cell wall contains β-glucan (β-1,3/1,6, distinct from oat's β-1,3/1,4) and chitin — both viscous, fermentable fibers that bind bile acids in small intestine. Liver compensates by synthesizing more bile from cholesterol, depleting hepatic cholesterol pool. LDL receptor upregulation increases LDL clearance. Mechanism is similar to oat beta-glucan but with chitin contributing additional binding capacity.
Muscle protein synthesis via amino acid delivery
Mycoprotein provides a complete amino acid profile (PDCAAS ~0.99, comparable to milk and beef) with sufficient leucine to trigger anabolic signaling at doses >=40 g protein. The finding of more MPS than leucine-matched milk protein suggests possible additional effects beyond leucine, perhaps prebiotic/fiber-derived metabolites or unique fungal amino acid signaling not yet fully characterized.
Prebiotic/SCFA production from fungal fiber
Chitin and β-glucan from fungal cell walls are fermented by colonic bacteria producing short-chain fatty acids (acetate, propionate, butyrate). Increased Bifidobacteria and Faecalibacterium prausnitzii observed with mycoprotein consumption. May contribute to anti-inflammatory effects, gut health, and possibly indirect metabolic benefits.
Glycemic load reduction (viscous fiber gel)
β-glucan and chitin form viscous gel in stomach/small intestine, slowing gastric emptying and glucose diffusion. Reduces postprandial glucose excursion and may improve insulin sensitivity over time. Mechanism is identical to oat beta-glucan glucose effect.
Clinical trials
Randomized double-blind parallel-group trial (Monteyne AJ, Coelho MOC, Porter C, Abdelrahman DR, Jameson TSO, Jackman SR, Blackwell JR, Brook MS, Murton AJ, Alamdari N, Stephens FB, Wall BT 2020, Am J Clin Nutr 112(2):318-333, doi:10.1093/ajcn/nqaa092).
20 resistance-trained healthy young males (age 22 ± 1 y, BMI 25 ± 1) under primed continuous L-[ring-2H5]phenylalanine infusion. Ingested either 31 g milk protein (26.2 g protein, 2.5 g leucine) or 70 g mycoprotein (31.5 g protein, 2.5 g leucine — leucine-matched) following unilateral resistance exercise (contralateral leg as resting control).
Single bolus of mycoprotein stimulated resting and post-exercise muscle protein synthesis to a greater extent than leucine-matched bolus of milk protein. Statistically significant superiority of mycoprotein vs milk protein in both rested and exercised muscle. Foundational evidence that mycoprotein is at least equivalent to and possibly superior to dairy protein for muscle anabolism — surprising given its lower leucine content per gram.
Comprehensive symposium review (Coelho MOC, Monteyne AJ, Dunlop MV, Harris HC, Morrison DJ, Stephens FB, Wall BT 2019, J Nutr 149(2):432S-440S, doi:10.1093/jn/nxy253).
Review of mycoprotein clinical literature — 13 human studies investigating health properties of mycoprotein.
Documented evidence of: (1) sustained satiety (multiple acute meal trials), (2) improved metabolic profiling — 5 of 9 trials found improved blood lipid levels, with cholesterol reductions 9-13% in meaningful intervention trials, (3) muscular protein synthetic response equivalent to milk/whey, (4) glucose and insulin control benefits, (5) low allergic reaction incidence. Concluded mycoprotein has substantial nutritional, health, and environmental benefits warranting incorporation into healthful diets.
Investigator-blind randomized crossover controlled trial (Farsi DN, Gallegos JL, Koutsidis G, Nelson A, Finnigan TJA, Cheung W, Munoz-Munoz JL, Bonham KW, Jhong J, Harvey DH, Commane DM 2023, Eur J Nutr 62(5):2169-2179, doi:10.1007/s00394-023-03110-2).
20 metabolically healthy adult males consumed 240 g/day red and processed meat for 14 days followed by mycoprotein, OR vice versa (crossover design). Blood biochemical indices were a priori secondary endpoints.
Mycoprotein consumption reduced total cholesterol by 6.74% (p=0.02) and LDL cholesterol by 12.3% (p=0.02) from baseline. Triglycerides not significantly different (+0.19 mmol/L, p=0.09). Confirms cholesterol-lowering benefit of mycoprotein vs red/processed meat — important context as red/processed meat replacement is the most common real-world use case.